Michael Buchert

Dr. Michael Buchert

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1996 in Nature
Verified
Journal Article
Closed access
HSHubert Schorle
Hubert Schorle
PMPascal Meier
Pascal Meier
MBMichael Buchert
Michael Buchert
RJRudolf Jaenisch
Rudolf Jaenisch
PMPamela J. Mitchell
Pamela J. Mitchell

18 May 2015 in Oncogene
Verified
Journal Article
Closed access
MBMichael Buchert
Michael Buchert
CBC J Burns
C J Burns
MEMatthias Ernst
Matthias Ernst

21 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MEMoritz F. Eissmann
Moritz F. Eissmann
CDChristine Dijkstra
Christine Dijkstra
AJAndrew Jarnicki
Andrew Jarnicki
TPToby Phesse
Toby Phesse
JBJamina Brunnberg
Jamina Brunnberg
MEMatthias Ernst
Matthias Ernst
The contribution of mast cells in the microenvironment of solid malignancies remains controversial. Here we functionally assess the impact of tumor-adjacent, submucosal mast cell accumulation in murine and human intestinal-type gastric cancer. We find that genetic ablation or therapeutic inactivation of mast cells suppresses accumulation of tumor-associated macrophages, reduces tumor cell proliferation and angiogenesis, and diminishes tumor burden. Mast cells are activated by interleukin (IL)-33, an alarmin produced by the tumor epithelium in response to the inflammatory cytokine IL-11, which is required for the growth of gastric cancers in mice. Accordingly, ablation of the cognate IL-33 receptor St2 limits tumor growth, and reduces mast cell-dependent production and release of the macrophage-attracting factors Csf2, Ccl3, and Il6. Conversely, genetic or therapeutic macrophage depletion reduces tumor burden without affecting mast cell abundance. Therefore, tumor-derived IL-33 sustains a mast cell and macrophage-dependent signaling cascade that is amenable for the treatment of gastric cancer.

1 April 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MEMatthias Ernst
Matthias Ernst
MNMeri Najdovska
Meri Najdovska
DGDianne Grail
Dianne Grail
TLTherese Lundgren-May
Therese Lundgren-May
MBMichael Buchert
Michael Buchert
BJBrendan J. Jenkins
Brendan J. Jenkins
Deregulated activation of STAT3 is frequently associated with many human hematological and epithelial malignancies, including gastric cancer. While exaggerated STAT3 signaling facilitates an antiapoptotic, proangiogenic, and proproliferative environment for neoplastic cells, the molecular mechanisms leading to STAT3 hyperactivation remain poorly understood. Using the gp130Y757F/Y757F mouse model of gastric cancer, which carries a mutated gp130 cytokine receptor signaling subunit that cannot bind the negative regulator of cytokine signaling SOCS3 and is characterized by hyperactivation of the signaling molecules STAT1 and STAT3, we have provided genetic evidence that IL-11 promotes chronic gastric inflammation and associated tumorigenesis. Expression of IL-11 was increased in gastric tumors in gp130Y757F/Y757F mice, when compared with unaffected gastric tissue in wild-type mice, while gp130Y757F/Y757F mice lacking the IL-11 ligand–binding receptor subunit (IL-11Rα) showed normal gastric STAT3 activation and IL-11 expression and failed to develop gastric tumors. Furthermore, reducing STAT3 activity in gp130Y757F/Y757F mice, either genetically or by therapeutic administration of STAT3 antisense oligonucleotides, normalized gastric IL-11 expression and alleviated gastric tumor burden. Surprisingly, the genetic reduction of STAT1 expression also reduced gastric tumorigenesis in gp130Y757F/Y757F mice and coincided with reduced gastric inflammation and IL-11 expression. Collectively, our data have identified IL-11 as a crucial cytokine promoting chronic gastric inflammation and associated tumorigenesis mediated by excessive activation of STAT3 and STAT1.

1 August 2017 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
JHJennifer Huynh
Jennifer Huynh
NENima Etemadi
Nima Etemadi
FHFrédéric Hollande
Frédéric Hollande
MEMatthias Ernst
Matthias Ernst
MBMichael Buchert
Michael Buchert

25 January 1999 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MBMichael Buchert
Michael Buchert
SSStefan Schneider
Stefan Schneider
VMVirginia Meskenaite
Virginia Meskenaite
MAMark T. Adams
Mark T. Adams
ECEli Canaani
Eli Canaani
NCNiall Corcoran
Niall Corcoran
The AF-6/afadin protein, which contains a single PDZ domain, forms a peripheral component of cell membranes at specialized sites of cell–cell junctions. To identify potential receptor-binding targets of AF-6 we screened the PDZ domain of AF-6 against a range of COOH-terminal peptides selected from receptors having potential PDZ domain-binding termini. The PDZ domain of AF-6 interacts with a subset of members of the Eph subfamily of RTKs via its COOH terminus both in vitro and in vivo. Cotransfection of a green fluorescent protein-tagged AF-6 fusion protein with full-length Eph receptors into heterologous cells induces a clustering of the Eph receptors and AF-6 at sites of cell–cell contact. Immunohistochemical analysis in the adult rat brain reveals coclustering of AF-6 with Eph receptors at postsynaptic membrane sites of excitatory synapses in the hippocampus. Furthermore, AF-6 is a substrate for a subgroup of Eph receptors and phosphorylation of AF-6 is dependent on a functional kinase domain of the receptor. The physical interaction of endogenous AF-6 with Eph receptors is demonstrated by coimmunoprecipitation from whole rat brain lysates. AF-6 is a candidate for mediating the clustering of Eph receptors at postsynaptic specializations in the adult rat brain.